- Anebulo Pharmaceuticals reported a **net loss of $2.1 million, or $(0.05) per share**, for the fourth quarter of fiscal year 2025, and a **net loss of $8.5 million, or $(0.25) per share**, for the full fiscal year 2025.  **[1815974_0001493152-25-016001_ex99-1.htm:2]** **[1815974_0001493152-25-016001_ex99-1.htm:3]** 
- As of June 30, 2025, the company had **$11.6 million in cash and cash equivalents**.  **[1815974_0001493152-25-016001_ex99-1.htm:2]** 
- On **September 25, 2025**, Anebulo initiated a Phase 1 single ascending dose (SAD) study for an intravenous (IV) formulation of its lead drug candidate, selonabant, for acute cannabis-induced toxicity in children, supported by a **$994,300 grant** from the National Institute on Drug Abuse (NIDA).  **[1815974_0001493152-25-016001_ex99-1.htm:1]** 
- The Board of Directors has approved a proposed **reverse stock split**, subject to stockholder approval, as part of a going private transaction intended to maintain fewer than 300 record holders and avoid SEC public reporting requirements.  **[1815974_0001493152-25-016001_ex99-1.htm:2]**

Anebulo Pharmaceuticals (ANEB)